MAZDUTIDE

Chemical Makeup:

• Molecular Formula: C210, H322, N46, O67
• Molecular Weight: 4563.14 g/mol
• Synonyms: IBI362, LY3305677, OXM-3, Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist.

[MAZDUTIDE] and Weight Regulation

In murine and primate models, [MAZDUTIDE] administration has been observed to induce significant reductions in body mass. Research suggests this effect is mediated through a dual pathway: GLP-1R activation suppresses caloric intake by delaying gastric emptying and modulating satiety signaling in the hypothalamus, while GCGR activation increases resting energy expenditure (REE). Studies indicate that the inclusion of the glucagon component allows for greater weight loss efficacy in obese phenotypes compared to GLP-1R mono-agonists alone.

[MAZDUTIDE] and Hepatic Lipid Metabolism

Investigation into [MAZDUTIDE] has focused heavily on its potential impact on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Preclinical data indicates that GCGR activation promotes hepatic fatty acid oxidation and reduces de novo lipogenesis. In relevant animal models, subjects treated with [MAZDUTIDE] displayed marked reductions in intrahepatic triglyceride content and improvements in histological markers of steatosis, suggesting a direct hepatoprotective mechanism independent of weight loss.

[MAZDUTIDE] and Glycemic Control

Research indicates that [MAZDUTIDE] exerts potent glucose-lowering effects. Through the GLP-1 receptor, it augments insulin secretion from pancreatic beta cells in response to elevated glucose levels while simultaneously inhibiting inappropriate glucagon secretion from alpha cells. Observations in diabetic murine models show improved glucose tolerance tests (GTT) and reductions in fasting plasma glucose, with efficacy comparable to or exceeding that of established GLP-1 analogues.

[MAZDUTIDE] and Cognitive Function

Emerging research has explored the neuroprotective potential of dual GLP-1R/GCGR agonism. In models of diabetes-associated cognitive dysfunction, administration of [MAZDUTIDE] was correlated with improved synaptic plasticity and reduced neuroinflammation. It is hypothesized that the peptide may cross the blood-brain barrier to influence neurotransmitter pathways involved in memory retention and cognitive resilience, potentially mitigating the neurodegenerative effects often comorbid with metabolic dysregulation.

If you're not 100% satisfied within the first 30 days, just send it back to us and we'll give you a full refund.

No need to worry about the return shipping - we've got you covered!

We offer fast and reliable shipping on all orders. You can expect to receive it within 7-12 business days based on your location.

Please contact our customer service team for assistance if you have any questions or concerns about your shipment.

Side Effects: 

In animal studies, observed adverse events were primarily gastrointestinal, including nausea, emesis, and decreased food consumption, particularly during the initial titration phase. Increases in heart rate have been noted in some preclinical subjects, attributed to the chronotropic effects of GCGR activation.

Withdrawal: 

No specific withdrawal syndrome has been characterized in non-clinical literature; however, cessation of administration in test subjects typically results in the gradual return of baseline metabolic parameters (e.g., regain of body mass and reversion of glycemic indices).